Prophylaxis of invasive aspergillosis with voriconazole or caspofungin during building work in patients with acute leukemia

Haematologica

Volumn 95, Issue 6, 2010, Pages 996-1003

  Chabrol, Amélie ^a   Cuzin, Lise ^a   Huguet, Françoise ^a   Alvarez, Muriel ^a   Verdeil, Xavier ^a   Linas, Marie Denise ^a   Cassaing, Sophie ^a   Giron, Jacques ^a   Tetu, Laurent ^a   Attal, Michel ^a   Récher, Christian ^a  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

Acute leukemia; Antifungal prophylaxis; Building work; Caspofungin; Invasive aspergillosis; Voriconazole

Indexed keywords

CASPOFUNGIN; CORTICOSTEROID DERIVATIVE; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; COHORT ANALYSIS; CONFUSION; CONSTRUCTION WORK; CONTROLLED STUDY; CYTOGENETICS; DISEASE DURATION; DRUG WITHDRAWAL; FEMALE; HALLUCINATION; HUMAN; INCIDENCE; INFECTION RISK; INVASIVE ASPERGILLOSIS; LIVER TOXICITY; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SIDE EFFECT; SINUS BRADYCARDIA; TOBACCO DEPENDENCE; ZYGOMYCOSIS;

EID: 77953194474     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.012633     Document Type: Article

References (26)

1. Pfaller MA. Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis. 2006;43(Suppl 1):S3-14.
2. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347(6):408-15.
3. Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis. 2007;44(10):1289-97.
4. Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica. 2006;91(8): 1068-75.
5. Caillot D, Mannone L, Cuisenier B, Couaillier JF. Role of early diagnosis and aggressive surgery in the management of invasive pulmonary aspergillosis in neutropenic patients. Clin Microbiol Infect. 2001;7(Suppl 2):54-61.
6. Oren I, Haddad N, Finkelstein R, Rowe JM. Invasive pulmonary aspergillosis in neutropenic patients during hospital construction: before and after chemoprophylaxis and institution of HEPA filters. Am J Hematol. 2001;66(4):257-62.
7. Cornet M, Fleury L, Maslo C, Bernard JF, Brucker G. Epidemiology of invasive aspergillosis in France: a six-year multicentric survey in the Greater Paris area. J Hosp Infect. 2002;51(4):288-96.
8. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis. 2001;32(3):358-66.
9. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Eng J Med. 2007; 356 (4): 348-59.
10. Vonberg RP, Gastmeier P. Nosocomial aspergillosis in outbreak settings. J Hosp Infect. 2006;63(3):246-54.
11. Alberti C, Bouakline A, Ribaud P, Lacroix C, Rousselot P, Leblanc T, et al. Relationship between environmental fungal contamination and the incidence of invasive aspergillosis in haematology patients. J Hosp Infect. 2001;48(3):198-206.
12. Weber SF, Peacock JE Jr, Do KA, Cruz JM, Powell BL, Capizzi RL. Interaction of granulocytopenia and construction activity as risk factors for nosocomial invasive filamentous fungal disease in patients with hematologic disorders. Infect Control Hosp Epidemiol. 1990;11(5):235-42.
13. Tamburini J, Elie C, Bardet V, Chapuis N, Park S, Broët P, et al. Constitutive phosphoinositide 3-kinase/Akt activation represents a favourable prognostic factor in de novo acute myelogenous leukemia patients. Blood. 2007;110(3):1025-8.
14. Pigneux A, Perreau V, Jourdan E, Vey N, Dastugue N, Huguet F, et al. Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial results. Haematologica. 2007;92(10):1327-34.
15. Huguet F, Leguay T, Raffoux E, Thomas X, Beldjord K, Delabesse E, et al. Pediatricinspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol. 2009;27(6):911-8.
16. Diviné M, Casassus P, Koscielny S, Bosq J, Sebban C, Le Maignan C, et al. Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol. Ann Oncol. 2005;16(12): 1928-35.
17. Rea D, Legros L, Raffoux E, Thomas X, Turlure P, Maury S, et al. High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia. Leukemia. 2006;20(3):400-3.
18. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood. 2000; 96(13):4075-83.
19. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813-21.
20. Bocquet P, Aggoune M, Aussant M, Rykner G, Brucker G. Aspergillose invasive nosocomiale et travaux hospitaliers: recommandations. Paris: Doin, 1993.
21. Berthelot P, Loulergue P, Raberin H, Turco M, Mounier C, Tran Manh Sung R, et al. Efficacy of environmental measures to decrease the risk of hospital-acquired aspergillosis in patients hospitalized in haematology wards. Clin Microbiol Infect. 2006;12(8):738-44.
22. Leenders AC, van Belkum A, Behrendt M, Luijendijk A, Verbrugh HA. Density and molecular epidemiology of Aspergillus in air and relationship to outbreaks of Aspergillus infection. J Clin Microbiol. 1999;37(6):1752-7.
23. ANAES. Hygienes 2000 ANAES. Prévention du risque aspergillaire chez les patients immunodéprimés (hématologie, transplantation). Hygiènes 2000;VIII(6): 336-501.
24. Vehreschild JJ, Bohme A, Buchheidt D, Arenz D, Harnischmacher U, Heussel CP, et al. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). J Infect. 2007;55(5):445-9.
25. ECIL Maertens J. Primary antifungal prophylaxis in leukaemia patients. Eur J Cancer. 2007;S5:43-8.
26. Siwek GT, Pfaller MA, Polgreen PM, Cobb S, Hoth P, Magalheas-Silverman M, et al. Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis. Diagn Microbiol Infect Dis. 2006;55(3):209-12.